Abstract
Active targeting with controlled delivery of anti-inflammatory drugs to the bone is not sufficiently explored. In this study, concise and novel synthesis of a hydroxy-bisphosphonic acid (HBPA) prodrug containing ibuprofen is described. The key step consisted of preparing the HBPA function from a carboxylic acid precursor, in mild conditions and using appropriate Arbuzov reactions with tris(trimethylsilyl)phosphite. This prodrug would be an excellent candidate for the treatment of bone inflammation diseases such as rheumatoid arthritis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
